Study Evaluating EKB-569 in Advanced Colorectal Cancer
NCT00072748
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
63
Enrollment
INDUSTRY
Sponsor class
Conditions
Colorectal Neoplasms
Colonic Neoplasms
Rectal Neoplasms
Interventions
DRUG:
EKB-569
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer